Home / Health / Zydus gets DCGI approval for phase-3 clinical trials of Covid-19 therapy

Zydus gets DCGI approval for phase-3 clinical trials of Covid-19 therapy

Trials will involve use of Cadila's biological therapy Pegylated Interferon alpha-2b in India

Coronavirus, vaccine, covid, drugs, clinical trials

Premium

The therapy was found to have significantly increased viral reduction and reduced the need for supplemental oxygen in moderate Covid-19 patients

Vinay Umarji Ahmedabad

2 min read Last Updated : Dec 04 2020 | 10:08 PM IST

Cadila Healthcare Ltd (Zydus Cadila) has obtained approval from the Drugs Controller General of India (DCGI) to start the phase-3 clinical trial on Covid-19 patients with its biological therapy, Pegylated Interferon alpha-2b, ‘PegiHepTM’.

Last month, Zydus Cadila had announced "successful" completion of phase two clinical trial of the biological therapy on Covid-19 patients, paving way for phase three trials in India. Cadila had stated that the open-label, randomized, comparator controlled study was conducted on 40 adult patients with moderate Covid-19 disease.

Of these, 95 per cent subjects in the test who received a single dose of PegiHepTM along with standard

Topics : Coronavirus Zydus Cadila Coronavirus Tests Coronavirus Vaccine

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in